Alogabat

Alogabat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7816 and RO7017773) is an α₅ subunit-containing GABA_A receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.^[1][2][3][4] It is taken by mouth.^[1]

Other namesGABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773

Routes of
administrationOral^[1]

Drug classα₅ subunit-containing GABA_A receptor positive allosteric modulator

CAS Number

• 2230009-48-8

Quick facts Clinical data, Other names ...

Alogabat

Clinical data
Other names	GABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773
Routes of administration	Oral[1]
Drug class	α5 subunit-containing GABAA receptor positive allosteric modulator
Identifiers
IUPAC name 6-[[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide
CAS Number	2230009-48-8
PubChem CID	134588268
DrugBank	DB18708
ChemSpider	115006746
UNII	0HPA4GK3UH
KEGG	D12382
ChEMBL	ChEMBL5095259
Chemical and physical data
Formula	C21H23N5O4
Molar mass	409.446 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C
InChI InChI=1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27) Key:ACZCJTHHWMBFKC-UHFFFAOYSA-N

Close

As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome.^[1][2] It is under development by Roche.^[1][2]